# Description:

This consultation seeks views on the updated Management of Angle-Closure Glaucoma guidance. The update incorporates the impact of new imaging modalities and its findings on the management of retinal vein occlusion. Recommendation on the use of intravitreal agents in the management of retinal vein occlusion have been updated to reflect the increasing body of literature on its use along with the impact this treatment has on the natural history and complications of retinal vein occlusion.

We are consulting on draft guidance for use primarily by ophthalmologists, providing them with evidence-based, clinical guidance for the appropriate management of different aspects of ACG. The foundations of the guidelines are based on evidence taken from the literature and published trials of therapies as well as consensus opinion of a representative expert panel convened by the RCOphth with an interest in this condition.

The scope of the guideline is limited to current diagnostic tools, management, service set-up and delivery to facilitate delivery of optimal clinical care pathways and management for patients with ACG.

We would like your feedback on the draft guidance relating to:

* The comprehensiveness and applicability of the guideline, are any points/factors missing?
* The content and clarity of the guideline and its suitability to different environments
* The interpretation of the evidence available to support its recommendations
* The likely impact on patient groups affected by the guideline
* The likely impact / ability of the health service to implement the recommendations will individuals/departments will attempt to follow the guidance - if so why? And if not, why not?

# Consultation period:

13 October 2021 to 5 November 2021 17:00

# Consultation document:

* [Management of Angle-Closure Glaucoma Clinical Guideline](https://www.rcophth.ac.uk/wp-content/uploads/2021/10/The-Management-of-Angle-Closure-Glaucoma-Clinical-Guidelines.pdf)
* [Management of Angle-Closure Glaucoma Clinical Guideline (Executive Summary)](https://www.rcophth.ac.uk/wp-content/uploads/2021/10/The-Management-of-Angle-Closure-Glaucoma-Clinical-Guidelines-Executive-Summary.pdf)

# How to respond:

* Send your comments to us
* You must use the Comments form
* Comments must be submitted by 17:00 on 1 November 2021
* Send your comments to [barny.foot@rcophth.ac.uk](mailto:barny.foot@rcophth.ac.uk)

# 

# About us

The Royal College of Ophthalmologists (RCOphth) is the only professional body for eye doctors, who are medically qualified and have undergone or are undergoing specialist training in the prevention, treatment and management of eye disease, including surgery. As an independent charity, we pride ourselves on providing impartial and clinically based evidence, putting patient care and safety at the heart of everything we do. Ophthalmologists are at the forefront of eye health services because of their extensive training and experience.

RCOphth received its Royal Charter in 1988 and has over 3,500 members in the UK and overseas. We are not a regulatory body, but we work collaboratively with government, health departments, charities and eye health organisations to develop recommendations and support improvements in the co-ordination and management of hospital eye care services both nationally and regionally.

[www.rcophth.ac.uk](http://www.rcophth.ac.uk)

|  |  |
| --- | --- |
|  | Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly. |
| Organisation name – stakeholder or respondent (if you are responding as an individual rather than an organisation please leave blank): | [**Insert organisation name**] |
| Disclosure  Please disclose any past or current, direct or indirect links to, or funding from, the Shares held by self or family in industry related to device, instrument or pharmaceutical.  Membership on advisory committee, board, review panel of industry with or without remuneration.  Official position (e.g. Director) or Employment (primary or secondary job). | [**Insert disclosure here**] |
| Name of commentator person completing form: | [**Insert your name here**] |

|  |  |  |
| --- | --- | --- |
| **Comment number** | **Section** | Comments  Insert each comment in a new row.  Do not paste other tables into this table because your comments could get lost – type directly into this table. |
| 1 |  |  |
| 2 |  |  |
| 3 |  |  |
| 4 |  |  |
| 5 |  |  |
| 6 |  |  |
| Insert extra rows as needed |  |  |

|  |
| --- |
| **Checklist for submitting comments**   * Use this comment form and submit it as a Word document (not a PDF). * Complete the disclosure about links with, or funding from, the industry. * Include section number of the text each comment is about e.g. introduction * Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation. * Do not paste other tables into this table – type directly into the table. * Underline and highlight any confidential information or other material that you do not wish to be made public. * Do not include medical information about yourself or another person from which you or the person could be identified. * Spell out any abbreviations you use * For copyright reasons, comment forms do not include attachments such as research articles, letters or leaflets. We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.   **Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all. |